Dr. Sean I. Savitz, Director of the Institute for Stroke and Cerebrovascular Diseases, discussed the advancements of cell-based therapies in stroke care.

This area has seen significant progress in recent years, with multiple ongoing clinical trials. One critical aspect under scrutiny is identifying which patients would derive the most benefit from these therapies. Notable breakthroughs include the safe use of bone marrow-derived cells through an allogenic approach and promising preclinical studies supporting the utilization of bone marrow stromal cells (BMSCs) to enhance patient recovery after reperfusion therapy. These breakthroughs represent a promising frontier in the landscape of stroke care.